Thispaper reviews sleep disturbances in patients with major depressive disorders and the effects ofdifferent classes ofantidepressants on sleep. It is clearfrom the studies reviewed that not all antidepressants improve sleep, and, indeed, some worsen sleep disturbances in patients with depression. Whether sleep is improved orfurther disrupted is ofhigh clinical significance, because persistent sleep problems elevate the risk ofrelapse, recurrence, or suicide, as well as the needfor augmenting medications. (Can J Psychiatry 2000;45:803-809) 
A s assessed by laboratory studies, sleep abnormalities in those with major depressive disorders can be classified as difficulties initiating and maintaining sleep, abnormal sleep architecture, and disruptions in the timing of rapid eye movement (REM) sleep. Sleep initiation and maintenance difficulties include prolonged sleep latency (sleep onset insomnia), intermittent wakefulness and sleep fragmentation during the night, early morning awakenings with an inability to return to sleep, reduced sleep efficiency, and decreased total sleep time. With regard to sleep architecture, abnormalities have been reported in the amounts and distribution of nonrapid eye movement (NREM) sleep stages across the night. These include increased light, stage 1 sleep and reductions in the amount ofdeep, slow-wave (stages 3 and 4) sleep. REM sleep disturbances in patients with depression include a short latency (65 minutes) to the first REM sleep, a prolonged first REM sleep period, and increased total REM sleep time, particularly in the first one-half of the night (1) (2) (3) .
Sleep disturbances are generally more prevalent among inpatients with depression (80%), whereas only 40% to 60% of outpatients show sleep abnormalities (4 or from those with other psychiatric disorders, prompting some researchers to conclude that clusters or combinations of sleep variables better describe the nature of sleep disturbance in patients with depression (5) . Thase has also suggested that approximately 30% of patients with depression have hypersomnia rather than insomnia as the dominant sleep abnormality (6) .
Clinical Relevance of Sleep to Depression
Although there is some disagreement as to which specific sleep EEG variables best characterize patients with depression, the importance ofthe relation between sleep and depression is clear. Persistent sleep disturbance is associated with significant risk of both relapse and recurrence (7) (8) and increased risk of suicide (9) . As well, in at least some studies, sleep variables such as REM latency have also been shown to predict treatment response and the clinical course of illness (10) (11) (12) (13) (14) (15) . It has also recently been suggested that the nature of the sleep disturbance at initial clinical presentation may be relevant to the choice of antidepressant medications and the likelihood of experiencing treatment-emergent side effects (16) .
Antidepressant Effects on Sleep in Patients With Depression
Most antidepressant medications suppress REM sleep, and it has been suggested that the improvement in the symptoms of depression is related to REM sleep deprivation (17) . However, not all antidepressants reduce REM sleep (18) (19) (20) . Moreover, antidepressant effects are not restricted to REM sleep; they also include alterations in sleep consolidation and sleep architecture that may be relevant both to clinical response and to the need for concomitant or augmentive treatment.
Tricyclics
With the exception of iprindole and trimipramine, tricyclic antidepressants (TCAs) are potent REM sleep suppressors, prolonging REM latency and decreasing the total amount of REM sleep time (17, (21) (22) (23) (24) . Clomipramine and desipramine are 2 ofthe most potent REM-suppressing TCAs, followed by imipramine and nortriptyline (25) (26) (27) (28) (29) . Clomipramine, desipramine, and amitriptyline also significantly increase stage I sleep and decrease sleep efficiency over baseline levels (29) .
Since clomipramine has stronger serotonergic reuptake inhibiting effects than other TCAs, it is not surprising that it has the most alerting effects on sleep (30) . Thus, clomipramine is probably best described as a serotonergic antidepressant rather than a traditional TCA (27) .
Interestingly, clinical response to amitriptyline and clomipramine appears to be related to the degree ofREM sleep suppression (31) (32) (33) , which supports the findings of Vogel and others (17) . As mentioned above, response to trimipramine is not related to a decrease in the amount ofREM sleep (22) (23) (24) .
Monoamine Oxidase Inhibitors
Monoamine oxidase inhibitors (MAOIs) have also been shown to suppress REM sleep in patients with depression, even eliminating REM sleep in some patients (30) . Relative to TCAs, the effects are delayed; they are, however, associated with a substantial REM rebound upon withdrawal (34) (35) . This class of antidepressants also appears to reduce total sleep time and may decrease sleep efficiency (35) .
By contrast, a study published in 1989 indicated that reversible MAOIs, such as moclobemide, may actually enhance REM sleep, decreasing both REM latency and the total amount of REM time (36) . In the same study, moclobemide was shown to improve sleep efficiency in patients with depression. A more recent study indicated decreased total sleep time, increased sleep latency, increased wakefulness, and prolonged REM latency after 4 weeks of 450 mg daily treatment with moclobemide. However, only the effects on REM latency were statistically significant (37) . Thus, it remains equivocal whether moclobemide enhances or suppresses REM sleep.
Selective Serotonin Reuptake Inhibitors
Unlike the TCAs and older MAOIs, whose antidepressant properties were discovered by serendipity, selective serotonin reuptake inhibitors (SSRIs) were specifically developed as antidepressants based on existing data indicating that serotonergic neurotransmission was compromised in those with depression (38) . Most published studies on SSRI effects on sleep have focused on fluoxetine.
Fluoxetine. Although Vogel and others (17) suggested that the REM -suppressing effects of fluoxetine were quite large, sleep studies in patients with depression have not supported this view. Fluoxetine does appear to significantly decrease total REM sleep time, but it is generally only a 3% to 5% reduction. The effects on REM latency, however, are substantial, virtually doubling the latency compared with baseline (39) (40) (41) (42) .
All 4 of these studies have also reported significantly increased stage 1 sleep for patients on fluoxetine. In support of an earlier study (43), 2 have shown increased wakefulness on this SSRI, either in the total number of awakenings or in decreased sleep efficiency (39, 42) . A large-scale, double-blind comparison between 2 antidepressants indicated that the 57 patients treated with fluoxetine showed significantly decreased sleep efficiency, an increase in the number and percentage of awakenings, decreased slow-wave sleep (stages 3 and 4), an increase in REM latency from 87 to 153 minutes, and a 3.5% decrease in total REM time, relative to baseline (44) . Moreover, the sleep effects offluoxetine were similar in both responders and nonresponders. There was no evidence to suggest that clinical response was related to the degree of REM sleep suppression, in contrast to some studies ofTCAs (31) (32) (33) . A preliminary study suggests that the alerting effects offluoxetine may also be evident in children and adolescents with depression, although REM sleep measures were largely unaffected by treatment (45) .
A more recent study ofthe longer-term effects offluoxetinein 36 acute-phase responders reported significantly reduced sleep efficiency, decreased stage 2 sleep, increased stage I sleep, prolonged REM latency, and a 3.4% reduction in REM time at 10 weeks of treatment (46) . After 30 weeks of treatment, REM latency remained longer and the percentage of stage 1 sleep was still elevated, compared with baseline. Thus, although there is some adaptation to fluoxetine, the alerting effects on sleep are still present after 30 weeks of treatment. Postdiscontinuation was associated with some REM rebound, although most sleep variables did not differ from baseline. Buysse and others, however, have shownthat the effects offluoxetine on REM and slow-wave sleep persist for at least 4 weeks postdiscontinuation in women with depression (47) .
Several studies have also shown that fluoxetine is associated with significant eye movement and motoric abnormalities during sleep, particularly during lighter NREM sleep stages. Fluoxetine-induced oculomotor abnormalities occur in 30% to 80% of adult patients (48) (49) (50) and may also be evidentin children and adolescents with depression (45) . Although TCAs have also been reported to exacerbate periodic limb movements during sleep (51), the incidence is stronger forthe SSRIs. Two additional reports indicate that fluoxetine or paroxetine exacerbate bruxism (52) (53) . (Note that in all the studies from our own group reported above, patients with depression were excluded from study if periodic limb movements or bruxism were noted at baseline.) Thus, it appears that fluoxetine (and perhaps other SSRIs) exacerbate preexisting conditions and induce oculomotor abnormalities in many patients. These adverse effects may also persist postdiscontinuation.
Paroxetine. In 16 patients with depression treated with paroxetine 20 mg daily for 4 weeks, the number of awakenings and the number of sleep stage shifts (a measure of consolidation within sleep) increased significantly from baseline (54) . The amount of REM sleep decreased by about 9%, whereas REMlatency more than doubled on treatment. Moreover, discontinuation of paroxetine was associated with a significant REM rebound, well above baseline levels. This study also noted that REM sleep effects were comparable in both responders and nonresponders, indicating that the REM sleep changes were not related to clinical response-as reported previously with fluoxetine (44) . Notably, however, paroxetine is associated with subjective sleep improvement but no systematic change in sleep polysornnography in primary insomnia (55) . A recent study has shown that paroxetine combined with total sleep deprivation induced a rapid antidepressant response in 9 out of 13 elderly patients with depression. Both the percentage ofresponders and the time to respond were significantly improved on a regime ofparoxetine plus sleep deprivation, compared with a regime of monotherapy with paroxetine or nortriptyline. Sleep architecture was not significantly altered by paroxetine (56) . Thus, paroxetine does not appear as alerting to sleep as fluoxetine; there are, however, substantially fewer studies upon which to base this conclusion.
Sertraline. As with paroxetine, there are few published studies on objective sleep effects, and only 1 report was found for patients with depression. In a 6-week placebo-controlled trial, 23 patients with depression showed both prolonged sleep latency and decreased total REM time, accompanied by decreased total sleep time in response to paroxetine (57) . No other significant effects were noted. Beyond this, no further published reports were found for patients with depression.
Unpublished data from the University ofTexas Southwestern Medical Center indicate increased wakefulness and stage 1 sleep, prolonged REM latency, and an approximate 6% reduction in REM time in 3 patients with depression after 12 to 24 weeks of treatment, consistent with published reports on other SSRIs.
Other SSRIs
Fluvoxamine also appears to be alerting to sleep in patients with depression. Kupfer and others reported longer sleep latency, more awake time, increased stage 1 sleep, 3 times longer REM latency, and dramatically reduced REM sleep time (10%) after 3 weeks oftreatment with fluvoxamine in 17 patients with depression (27) . The alerting and REM sleep effects were also fast-acting, evident after only 1 or 2 days on the medication. This study confirmed an earlier report of the immediate effects of fluvoxamine on sleep in patients with depression (58) . Zimelidine also increases the amount of wakefulness during the night and shows REM-suppressing effects in patients with depression (59, 28) . Conversely, citalopram appeared to suppress REM sleep and increase REM latency without significant deleterious effects on sleep continuity or wakefulness during the night in a study of patients over 6 weeks of treatment (60) . Again, clinical response to treatment was not significantly related to the changes in REM sleep.
Other Serotonergic Antidepressants
Trazodone and nefazodone both affect serotonergic neurotransmission but are pharmacologically distinct from the SSRIs (and from each other) (19, 30) . Their effects on sleep also differ dramatically from the SSRIs.
Trazodone. In an early report, Mouret and others showed no evidence ofdecreased REM sleep time in 10 patients with depression treated for 5 weeks with trazodone (61) . Sleep assessments were conducted at baseline and again at the end of treatment. Trazodone was associated with increased total sleep time, enhanced slow-wave sleep, a decrease in nocturnal awakenings, and prolonged REM latency. An additional study of 6 patients with depression and insomnia confirmed this report and found shorter sleep latency, increased total sleep time, enhanced slow-wave sleep, and slightly prolonged REM latency; however, no effect on total REM time was found over the course of 5 weeks oftreatment. Due to the sample size, the statistical significance of these effects was not evaluated (62) .
In striking contrast, van Bemmel and others reported no change in slow-wave sleep and 5% to 9% REM sleep suppression in 8 patients with depression, also over the course of 5 weeks oftreatment (63) . This study, however, used substantially lower doses of trazodone than did the Scharf and Sachais study (62) and nearly one-half the dose of the Mouret and others (61) study.
Although no laboratory assessment ofsleep was included, Jacobsen reported improved subjective sleep with the coadministration of trazodone in 20 out of 21 patients with depression who had MAOI-associated insomnia and in 26 out of 27 patients with insomnia who were treated with other psychotropic medications (64) . Trazodone augmentation has also been shown to improve subjective insomnia in other studies (65, 66) and is widely prescribed as an adjunct treatment. In a later, lab-based study, augmentation of brofaromine, (a MAOI with trazodone) increased deeper stages of NREM sleep and improved subjective sleep (67) .
Nevertheless, discrepancies in the effect oftrazodone on objective sleep data remain to be resolved. With regard to clinical impression, trazodone is viewed as a sedating antidepressant (64) and thus is likely to have deleterious effects on daytime alertness, particularly at higher doses.
NeJazodone. Nefazodone may also be unique in that it does not appear to suppress REM sleep in either healthy controls or in patients with depression (19, 68, 30) . In an open-label preliminary study of the effect of 400 mg to 600 mg (200 mg to 300 mg twice daily) of nefazodone on sleep in 10 patients with depression, Armitage and others reported decreased awake and movement time and short duration arousals, as well as increased stage 2 sleep, but noted minimal effects on REM sleep (19) . Trends toward decreased stage I sleep were also found. All patients were treatment responders, suggesting that the clinical efficacy of nefazodone was not tied to REM sleep suppression.
These effects were confirmed in 2 subsequent double-blind studies comparing nefazodone and fluoxetine (39) (40) . Moreover, these data were part ofa multicentre trial and were subsequently included in a pooled analysis (44) . The latter report included baseline to endpoint (last observation carried forward or at 8 weeks of treatment) sleep comparisons in 59 patients in the nefazodone arm of the protocol. Nefazodone significantly decreased the number ofnoctumal awakenings, improved sleep efficiency, enhanced stage 2 sleep, decreased slow-wave sleep, shortened REM latency, and resulted in a small (2%), but significant, increase in REM time. Restricting analysis to treatment responders produced very similar results, and thus, the clinical efficacy of nefazodone does not appear to be tied to REM sleep change. Scharfand others (69) have also reported primary effects ofnefazodone on sleep efficiency; the amount of wakefulness in 16 patients with depression was associated with no alterations in REM or slow-wave sleep. This study is highly relevant because all of the patients with depression had insomnia complaints. Collectively, these studies suggest that nefazodone may best be targeted toward patients with depression and insomnia or substantial intermittent wakefulness during sleep.
It is important to point out that the effects of nefazodone on sleep differ both from the SSRIs and from trazodone. Trazodone is primarily a 5-HT z antagonist, whereas the SSRIs inhibit 5-HT reuptake. By contrast, nefazodone possesses both 5-HT z antagonism and inhibits synaptic uptake of 5-HT.
Since nefazodone does not produce the alerting effects ofthe SSRIs on sleep or the slow-wave sleep enhancement of'trazodone, it is likely that the combination of serotonergic antagonism and reuptake inhibition produces its unique profile on sleep in patients with depression (30) . Interestingly, it is common clinical practice in the US to prescribe trazodone as an augmentive therapy, particularly with the SSRIs. This combination of 5-HT reuptake inhibition and 5-HT z antagonism is very similar to the pharmacological characteristics of nefazodone. It remains to be seen, however, whether the combination of trazodone and the SSRIs produces sleep effects similar to those observed with nefazodone.
Mirtazapine. Mirtazapine also acts on 5-HT z receptors and has been shown to shorten sleep latency, increase total sleep time, and improve sleep efficiency in patients with depression (70) . What is more, Carpenter and others have also shown mirtazapine to be effective as an augmenting treatment in refractory depression (71) . As observed with high doses oftrazodone and nefazodone, however, mirtazapine is sedating, as suggested by Thase (70) , and may be best targeted toward patients with depression and substantial . . msomma.
Azapirones
Azapirones are agonists of serotonergic neurotransmission at the 5-HT 1A receptor and include buspirone, gepirone, and ipsapirone. In a placebo-controlled study of 10 mg or 20 mg daily doses in 18 patients with depression, Gillin and others (72) demonstrated prolonged REM latency and a 5% to 8% reduction in total REM time in response to ipsapirone. Sleep effects were generally more pronounced in the higher-dose condition and included prolonged sleep onset. The effects in patients with depression did not differ from those observed in healthy control subjects. These findings contradict 2 early unpublished studies indicating that both ipsapirone and buspirone shorten REM latency in heathy control subjects (73) (74) . Thus, the effects of azapirones on sleep in any population remain controversial.
Other Antidepressants
Bupropion is typically viewed as a dopaminergic antidepressant, although recent preclinical evidence suggests that its effects are more selective for norepinephrine (75) . One studyof patients with depression also indicates that this antidepressant may not suppress REM sleep (76) . In 7 patients treated with bupropion (for an average of 16.4 ± 4.1 weeks), REMlatency was significantly shorter and REM sleep time was increased by about 8%, compared with baseline. If this studyis replicated, then bupropion joins iprindole, trimipramine, nefazodone, and perhaps moclobemide as an antidepressant with a mechanism of action not related to REM sleep suppression.
Mianserin is a tetracyclic antidepressant that acts as an antagonist on a number of monoamine receptors, including 5-HT z (30) . Its primary effect on sleep in depression is a significant increase in REM latency with no apparent reduction in total REM time. It does not appear to influence slow-wave sleep, but it does improve sleep continuity (71) . Mianserin, like trazodone, may also be a more sedating antidepressant.
Beyond this work, a recent MEDLINE search revealed no additional published studies ofantidepressant effects on sleep in patients with depression. Although some studies of venlafaxine and citalopram have been conducted in healthy volunteers, it is this author's opinion that the effects may differ substantially from those obtained in patients with depression in whom neurotransmitter and sleep abnormalities already exist (39, 44) . Clearly, additional research on the impact of newer antidepressants on sleep for patients with depression is warranted, particularly in longer-term treatment trials that better reflect clinical practice.
Clinical Relevance of Antidepressant Effects on Sleep
One important issue is the clinical relevance ofantidepressant effects on sleep. As noted above, most antidepressants are associated with significant improvement in subjective sleep, even those that are alerting. This raises the issue of whether patients notice the disturbance in objective sleep measures and whether it impacts on treatment or clinical course. Increases in motor activation and periodic limb movements associated with the SSRIs are likely to contribute to increased wakefulness and the alerting effects offluoxetine. In 1 study, it was noted that most events were intrusive and associated with EEG arousal (48) . Nevertheless, only 12% of men and 38% of women reported reduced sleep quality on fluoxetine. When specifically queried with regard to the number and duration of subjective awakenings, however, most patients did report an increase on treatment, compared with baseline (16) .
Thus, it appears that there is better correspondence between objective and subjective sleep data when specific, concrete questions are posed. Sleep quality and depth may be less tangible concepts; they have been shown to be poor correlates of objective sleep data, even in adults without depression (78) . Nevertheless, many patients, particularly men, do not appear to be sensitive to the alerting effects of the SSRIs.
There are additional data to support sex differences in the pharmacodynamics and pharmacokinetics ofantidepressants (79) and in their effects on sleep EEG (80) . Coupled with clear evidence that the pathophysiology ofdepression differs for men and women (4), it may well be time to factor sex into patient management strategies.
Improvement in sleep may also be associated both with increased compliance and with reduced treatment costs (44) . Recent data from the Texas and California Medicare and Medicaid studies indicate that the incidence ofcoprescription of hypnotic or anxiolytic agents is significantly higher with the SSRIs than with less alerting antidepressants such as nefazodone (81) . It is tempting to speculate that improvement in sleep is related to decreased need for augmentive therapies. From an economic viewpoint, however, reducing the need for augmentive or concomitant therapies dramatically reduces the cost of antidepressant treatment (81) .
Although it is known that persistent sleep disturbance is associated with increased risk for relapse, recurrence, and suicide (7) (8) (9) , it remains to be seen whether improvement or worsening of objective sleep measures is directly associated with clinical course.
Important for nonsleep specialists, the nature ofthe dominant sleep complaint at initial presentation may be very useful in determining treatment choices. For example, in those patients best characterized as hypersomniac, alerting antidepressants may produce more "normal" sleep architecture. Women with depression and insomnia may in the long run do better with a less alerting antidepressant because they are more likely to experience objective sleep disturbance. These women may also be more likely to require augmentative therapies when prescribed alerting antidepressants. Such speculations, however, await confirmation. Nonetheless, clinicians should be sensitive to the consequences ofsleep disturbances in patients with depression as well as to the potential sex differences in sleep and side effect profiles.
Finally, a notation is necessary regarding the use ofhypnotics as adjunctive agents, because this class of drugs is still the most common strategy for managing sleep problems in patients with depression. Studies indicate that subjective insomnia may be improved acutely, but the degree of daytime sedation may be greater than occurs with the use oftrazodone or mirtazapine (82) . There is additional concern regarding drug interaction effects using hypnotics as adjuncts to antidepressants: nefazodone plus triazolam, for example, raised plasma levels of this benzodiazepine by 500%. Thus, careful monitoring of blood levels is necessary when using this and other combinations (82) . Combining either hypnotics or serotonergic 5-HT2 compounds with antidepressant therapies that are already associated with sedation may be unwise.
Resume-Les effets des antidepresseurs sur le sommeil des patients souffrant de depression
Cet article examine les troubles du sommeil chez les patients souffrant de troubles depressifs majeurs et les effets de differents types d 'antidepresseurs sur le sommeil. Selon les etudes consultees, il est evident que les antidepresseurs n 'ameliorentpas tous le sommeil et qu 'enfait, certains aggravent les troubles du sommeil chez les patients deprimes. Il est de toute premiere importance clinique de determiner si le sommeil s 'ameliore ou se deteriore, parce que les troubles du sommeil persistants entrainent un risque accru de rechute, de recurrence ou de suicide ainsi que Ie besoin d'augmenter les medicaments.
